BriaCell Therapeutics Corp. ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price target of Yen7,600.00. Stephen Barker has given his Buy ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK ... Monday's Regular trading at $70.08 up $1.02 or 1.48%. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti ...

Daiichi Sankyo, an innovative global healthcare company, has established a state-of-the-art research laboratory in San Diego, California, US, dedicated to the development of robotics, automation and ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their ... M.D., trial investigator and UCLA Health Jonsson Comprehensive Cancer Center, said in a release.

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...